Key takeaways
- Haleon is partnering with CVS to build dedicated in-store shelves for GLP-1 side-effect remedies.
- The dual-placement retail strategy drove an average 24% sales increase per store in the first quarter of the year.
- Approximately 11% of Americans now take GLP-1 medications, driving massive demand for companion products.
- Haleon has also initiated talks with major big-box retailers Walmart and Target to expand this merchandising model.
What happened
Consumer healthcare giant Haleon announced it is actively partnering with major U.S. retail pharmacies, including CVS Pharmacy, to place over-the-counter remedies in dedicated, curated store sections targeting GLP-1 medication users. According to a company spokesperson, the dual-placement strategy—putting stomach and pain remedies both on standard aisles and on dedicated GLP-1 shelves—drove an average 24% sales increase per store during the first quarter of the year.
Why it matters
For patients obtaining weight-loss medications like semaglutide and tirzepatide through online telehealth providers, managing common gastrointestinal side effects is often a self-directed process. By organizing over-the-counter companion products like TUMS, Advil, and Biotène into dedicated "GLP-1 destination sets," major retailers are commercializing side-effect relief directly in the pharmacy aisle. This physical store restructuring makes it easier for cash-paying patients to locate supportive care, while signaling that consumer health conglomerates now view GLP-1 side effects as a highly lucrative, permanent retail category.
What the data says
The expansion of these curated retail sections is backed by significant sales data and broad demographic trends:
- Sales Growth: Haleon reported that placing products in dedicated GLP-1 store displays alongside core aisles yielded a 24% average sales lift per store. Curated items on these specialized shelves are currently outperforming the exact same products in stores without dedicated displays.
- Market Share: Haleon, which was spun off from GSK, currently holds the majority of GLP-1-designated shelf space at CVS.
- Patient Demographics: Data from analytics firm Gallup indicates that approximately 11% of Americans—more than 1 in 10 adults—are currently taking a GLP-1 weight-loss medication.
- Retail Expansion: In addition to its active partnership with CVS, Haleon confirmed it has held discussions with retail giants Walmart and Target regarding similar in-store merchandising strategies.
Common side effects associated with GLP-1 medications include nausea, vomiting, constipation, diarrhea, abdominal pain, stomach cramps, and acid reflux. By grouping medications like antacids, laxatives, stool softeners, and pain relievers together, retailers are addressing a wide spectrum of patient discomfort in a single location.
How it compares
For telehealth patients, managing medication side effects has historically involved consulting a virtual provider or shopping across multiple disparate aisles of a drug store. Telehealth companies frequently recommend specific active ingredients to combat the slow gastric emptying caused by GLP-1s, but patients are typically left to source these products independently.
Comparing this new retail model to traditional pharmacy layouts reveals a distinct shift. Previously, a patient experiencing nausea and constipation would have to navigate several separate sections of a store to find bismuth subsalicylate (such as Pepto-Bismol) and fiber supplements. The new "GLP-1 destination sets" centralize these products. Furthermore, because many telehealth patients pay out-of-pocket for their weight-loss programs, bundling these low-cost over-the-counter solutions provides a transparent, affordable way to manage care. Purchasing a generic store-brand antacid or a name-brand product like TUMS for $5 to $15 is significantly cheaper than seeking prescription-strength anti-nausea medications, which may carry additional copays or require extra virtual consultation fees.
How this fits the bigger picture
The rise of dedicated GLP-1 companion aisles reflects the massive, systemic footprint these weight-loss medications now have in the daily lives of millions of Americans. As clinical usage expands, the healthcare industry is shifting from simply selling the primary weight-loss hormone to building an entire commercial ecosystem around its secondary effects.
This development aligns closely with clinical discussions regarding patient wellness and body composition. For example, clinical data showing that up to 40% of GLP-1 weight loss can come from muscle has already forced telehealth buyers to focus on protein supplements and strength training, as explored in our coverage of GLP-1 muscle loss and body composition. Similarly, as patients navigate the daily physical realities of these medications, the demand for clear, accessible safety and symptom-management resources is rising.
This trend also connects to broader shifts in consumer habits. As detailed in our analysis of the rise of private GLP-1 telehealth, millions of patients are bypassing traditional, insurance-heavy medical routes in favor of cash-pay telehealth programs. Because these cash buyers often manage their treatment plans with minimal physical interaction with a doctor, retail pharmacies are stepping in to fill the counseling gap, using physical shelf organization to guide patients toward safe, self-administered side-effect relief.
What happens next
Patients can expect to see these dedicated GLP-1 companion displays roll out to more retail locations across the United States. While CVS has already expanded its product assortment to highlight both national and store-brand over-the-counter solutions, the outcomes of Haleon's talks with Walmart and Target will likely dictate how quickly these specialized sections appear in big-box retail environments. Additionally, consumer health manufacturers are expected to design new packaging, educational signage, and product bundles specifically tailored to help weight-loss patients navigate gastrointestinal transit changes.
CompareRx does not provide medical advice. Always consult your telehealth clinician or primary care physician before starting any over-the-counter treatments or combining companion medications with your prescribed GLP-1 regimen.